Recent Company News

• 03:36 AM ET Jul 21, 2025
  

  Bayer's Nubeqa receives EU approval in third indication for patients with advanced prostate cancer (€27.75, +0.07)

• 09:05 PM ET Jul 18, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 12:29 PM ET Jul 18, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 20-Jul

• 06:34 PM ET Jul 16, 2025
  

  FDA grants orphan drug designation to emodepside for GI infections caused by roundworm (€27.57, 0.00)

• 10:39 AM ET Jul 15, 2025
  

  FDA discloses paragraph IV patent certifications including Bayer's Vitrakvi

• 05:08 PM ET Jul 14, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:56 AM ET Jul 14, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:03 AM ET Jul 14, 2025
  

  Daré Bioscience announces interim Phase 3 results highlight potential of Ovaprene ($2.52, 0.00)

• 02:32 AM ET Jul 14, 2025
  

  FDA approves Finerenone for New Indication in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥ 40% (€27.34, 0.00)

• 11:33 AM ET Jul 10, 2025
  

  Bayer receives first approval worldwide for Lynkuet (elinzanetant) in the UK as treatment of moderate to severe vasomotor symptoms associated with menopause (€27.77, 0.00)